Natco Pharma Ltd

Natco Pharma Expands Global Footprint with 35.75% Stake in Adcock Ingram 🌍💊

- Natco Pharma proposes a 35.75% stake in Adcock Ingram, with Bidvest Group holding 64.25%.

- Adcock Ingram operates in Prescription, OTC, Hospital, and Consumer divisions.

- Top products: Panado, Corenza C, Epi-max, IV Solutions Viaflex, Allergex, and more.

- FY24 financials: $536M revenue, $78M EBITDA (15% margin), $45M net profit (8% margin).

- Strategic rationale: Global expansion, South Africa as Africa’s gateway, and Adcock’s market strength.

- Synergies: Revenue growth via distribution, cost efficiencies, and R&D collaboration.

- Bidvest Group, the other shareholder, reported $6.8B revenue in 2024.

- Natco will consolidate 35.75% of Adcock’s net profit.